An epstein-barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins

Pier Luigi Tazzari, Daniela De Totero, Andrea Bolognesi, Nicoletta Testoni, Stefano Pileri, Silvio Roncella, Gigliola Reato, Harald Stein, Marco Gobbi, Fiorenzo Stirpe

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background and Objectives. In this study we describe a newly established CD30+ Epstein Barr virus (EBV)-infected B cell line derived from an EBV infected B cell culture (utilized, once irradiated, as a feeder) which showed a B clonal rearrangement and strong CD30 antigen expression. Design and Methods. The cells injected into SCID mice were able to grow giving rise to CD30+ solid tumors with the morphologic features of an anaplastic large cell lymphoma (ALCL). Thus we tried to establish a model to investigate the potency of immunoconjugates containing a CD30 monoclonal antibody (Ber-H2) and ribosome-inactivating proteins (saporin, momordin and ricin A-chain) as toxic moi eties. Results. We observed a strong cytotoxic activity of the anti-CD30 immunotoxins on the in vitro growth of D430B cells. High levels of anti-tumor activity were also observed in vivo, in the SCID mouse model. Interpretation and Conclusions. The antitumor immunotoxin therapy was successful in our chosen animal model, the effecacy seeming to be associated with strength of CD30 expression. Our data suggest that immunotoxins should be tested (before use) on the tumor cells of the subject to be treated and that immunotoxins should be directed to different tumor-associated antigens to avoid selection of cell populations with different antigenic mosaics.

Original languageEnglish
Pages (from-to)988-995
Number of pages8
JournalHaematologica
Volume84
Issue number11
Publication statusPublished - Nov 1999

Fingerprint

Anaplastic Large-Cell Lymphoma
Immunotoxins
SCID Mice
Human Herpesvirus 4
Cell Line
CD30 Antigens
B-Lymphocytes
Ribosome Inactivating Proteins
Immunoconjugates
Ricin
Neoplasms
Poisons
Neoplasm Antigens
Animal Models
Cell Culture Techniques
Monoclonal Antibodies
Growth
Population

Keywords

  • B cell-derived ALCL
  • CD30
  • Immunotherapy
  • RIPs

ASJC Scopus subject areas

  • Hematology

Cite this

An epstein-barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins. / Tazzari, Pier Luigi; De Totero, Daniela; Bolognesi, Andrea; Testoni, Nicoletta; Pileri, Stefano; Roncella, Silvio; Reato, Gigliola; Stein, Harald; Gobbi, Marco; Stirpe, Fiorenzo.

In: Haematologica, Vol. 84, No. 11, 11.1999, p. 988-995.

Research output: Contribution to journalArticle

Tazzari, Pier Luigi ; De Totero, Daniela ; Bolognesi, Andrea ; Testoni, Nicoletta ; Pileri, Stefano ; Roncella, Silvio ; Reato, Gigliola ; Stein, Harald ; Gobbi, Marco ; Stirpe, Fiorenzo. / An epstein-barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins. In: Haematologica. 1999 ; Vol. 84, No. 11. pp. 988-995.
@article{25b1de6732f748beae4782e2cf481ab7,
title = "An epstein-barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins",
abstract = "Background and Objectives. In this study we describe a newly established CD30+ Epstein Barr virus (EBV)-infected B cell line derived from an EBV infected B cell culture (utilized, once irradiated, as a feeder) which showed a B clonal rearrangement and strong CD30 antigen expression. Design and Methods. The cells injected into SCID mice were able to grow giving rise to CD30+ solid tumors with the morphologic features of an anaplastic large cell lymphoma (ALCL). Thus we tried to establish a model to investigate the potency of immunoconjugates containing a CD30 monoclonal antibody (Ber-H2) and ribosome-inactivating proteins (saporin, momordin and ricin A-chain) as toxic moi eties. Results. We observed a strong cytotoxic activity of the anti-CD30 immunotoxins on the in vitro growth of D430B cells. High levels of anti-tumor activity were also observed in vivo, in the SCID mouse model. Interpretation and Conclusions. The antitumor immunotoxin therapy was successful in our chosen animal model, the effecacy seeming to be associated with strength of CD30 expression. Our data suggest that immunotoxins should be tested (before use) on the tumor cells of the subject to be treated and that immunotoxins should be directed to different tumor-associated antigens to avoid selection of cell populations with different antigenic mosaics.",
keywords = "B cell-derived ALCL, CD30, Immunotherapy, RIPs",
author = "Tazzari, {Pier Luigi} and {De Totero}, Daniela and Andrea Bolognesi and Nicoletta Testoni and Stefano Pileri and Silvio Roncella and Gigliola Reato and Harald Stein and Marco Gobbi and Fiorenzo Stirpe",
year = "1999",
month = "11",
language = "English",
volume = "84",
pages = "988--995",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "11",

}

TY - JOUR

T1 - An epstein-barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins

AU - Tazzari, Pier Luigi

AU - De Totero, Daniela

AU - Bolognesi, Andrea

AU - Testoni, Nicoletta

AU - Pileri, Stefano

AU - Roncella, Silvio

AU - Reato, Gigliola

AU - Stein, Harald

AU - Gobbi, Marco

AU - Stirpe, Fiorenzo

PY - 1999/11

Y1 - 1999/11

N2 - Background and Objectives. In this study we describe a newly established CD30+ Epstein Barr virus (EBV)-infected B cell line derived from an EBV infected B cell culture (utilized, once irradiated, as a feeder) which showed a B clonal rearrangement and strong CD30 antigen expression. Design and Methods. The cells injected into SCID mice were able to grow giving rise to CD30+ solid tumors with the morphologic features of an anaplastic large cell lymphoma (ALCL). Thus we tried to establish a model to investigate the potency of immunoconjugates containing a CD30 monoclonal antibody (Ber-H2) and ribosome-inactivating proteins (saporin, momordin and ricin A-chain) as toxic moi eties. Results. We observed a strong cytotoxic activity of the anti-CD30 immunotoxins on the in vitro growth of D430B cells. High levels of anti-tumor activity were also observed in vivo, in the SCID mouse model. Interpretation and Conclusions. The antitumor immunotoxin therapy was successful in our chosen animal model, the effecacy seeming to be associated with strength of CD30 expression. Our data suggest that immunotoxins should be tested (before use) on the tumor cells of the subject to be treated and that immunotoxins should be directed to different tumor-associated antigens to avoid selection of cell populations with different antigenic mosaics.

AB - Background and Objectives. In this study we describe a newly established CD30+ Epstein Barr virus (EBV)-infected B cell line derived from an EBV infected B cell culture (utilized, once irradiated, as a feeder) which showed a B clonal rearrangement and strong CD30 antigen expression. Design and Methods. The cells injected into SCID mice were able to grow giving rise to CD30+ solid tumors with the morphologic features of an anaplastic large cell lymphoma (ALCL). Thus we tried to establish a model to investigate the potency of immunoconjugates containing a CD30 monoclonal antibody (Ber-H2) and ribosome-inactivating proteins (saporin, momordin and ricin A-chain) as toxic moi eties. Results. We observed a strong cytotoxic activity of the anti-CD30 immunotoxins on the in vitro growth of D430B cells. High levels of anti-tumor activity were also observed in vivo, in the SCID mouse model. Interpretation and Conclusions. The antitumor immunotoxin therapy was successful in our chosen animal model, the effecacy seeming to be associated with strength of CD30 expression. Our data suggest that immunotoxins should be tested (before use) on the tumor cells of the subject to be treated and that immunotoxins should be directed to different tumor-associated antigens to avoid selection of cell populations with different antigenic mosaics.

KW - B cell-derived ALCL

KW - CD30

KW - Immunotherapy

KW - RIPs

UR - http://www.scopus.com/inward/record.url?scp=0032760122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032760122&partnerID=8YFLogxK

M3 - Article

C2 - 10553158

AN - SCOPUS:0032760122

VL - 84

SP - 988

EP - 995

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 11

ER -